alanine has been researched along with Benign Neoplasms in 94 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The potential use of OKN-007 in combination with neurotropic compounds such as the lanthionine ketamine esters is discussed for glioblastoma multiforme as well as for various other indications leading to dementia, such as aging, septic shock, and malaria infections." | 6.49 | Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines. ( Castro Faria Neto, HC; Floyd, RA; Hensley, K; Towner, RA; Zimmerman, GA, 2013) |
| "Closure decisions were made for breast cancer, pancreatic cancer, NSCLC, gastric cancer and TCC." | 2.90 | Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. ( Abdul Razak, AR; Awada, A; Baurain, JF; Bedard, PL; Brockstein, B; D'Adamo, D; de Vos-Geelen, JMPGM; DeGreve, J; DeJonge, M; Dickson, M; Evans, TRJ; Geary, D; Janisch, L; Jassem, J; Jones, RL; Kaye, SB; Khayat, D; Kristeleit, R; Maki, R; Medioni, J; O'Dwyer, PJ; Obel, J; Ratain, MJ; Rudin, C; Sawyer, M; Schwartz, G; Siu, LL; Undevia, S; Vitfell-Rasmussen, J; Walters, I, 2019) |
| " Most toxic effects were mild." | 2.76 | A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. ( de Braud, F; Feltquate, DM; Galbraith, S; Goss, G; Jayson, GC; Jonker, DJ; Kantor, J; Kollia, G; McArthur, GA; Mokliatchouk, O; Nuyten, DSA; Rosen, LS; Rustin, G; Sawyer, MB; Sweeney, CJ; Syed, S; Velasquez, L; Wilding, G, 2011) |
| " Throughout both phases, subjects were evaluated for adverse events (AEs) and best clinical response." | 2.76 | Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. ( Chemidlin, J; Fischer, B; Hurwitz, H; Kollia, G; LoRusso, P; Masson, E; Pilat, MJ; Shapiro, GI; Syed, S, 2011) |
| " The median time to reach the maximal plasma concentration of brivanib was 1 h, geometric mean maximal plasma concentration was 6146 ng/ml, mean terminal half-life was 13." | 2.75 | Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. ( Fischer, BS; Gan, J; Ganapathi, R; Gong, J; Iyer, R; Masson, E; Mekhail, T; Patricia, D; Pursley, J; Williams, D, 2010) |
| "These cancers are potential targets for selective chemotherapy with inhibitors of de novo adenine synthesis such as L-alanosine [L-2-amino-3-(N-hydroxy-N-nitrosamino) propionic acid]." | 2.74 | A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. ( Burris, HA; Kindler, HL; Oliff, IA; Sandler, AB, 2009) |
| "Autophagy is upregulated in many cancers and supports their growth, survival, and malignancy in a tumor cell-autonomous fashion." | 2.72 | Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity. ( Guo, JY; Lattime, EC; White, E, 2021) |
| "A total of 39 studies with 16,783 cancer cases and 23,063 control subjects were included in the meta-analysis on the basis of the inclusion and exclusion criteria." | 2.50 | PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies. ( Cheng, H; Lu, J; Qin, Q; Sun, X; Xu, L; Yang, X; Zhan, L; Zhang, C; Zhu, H, 2014) |
| " The potential use of OKN-007 in combination with neurotropic compounds such as the lanthionine ketamine esters is discussed for glioblastoma multiforme as well as for various other indications leading to dementia, such as aging, septic shock, and malaria infections." | 2.49 | Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines. ( Castro Faria Neto, HC; Floyd, RA; Hensley, K; Towner, RA; Zimmerman, GA, 2013) |
| " χ-MrIA reversed the behavioural signs of mechanical allodynia in a chronic constriction injury rat model but its chemically unstable N-terminal asparagine precluded long-term use in implanted pumps." | 2.48 | Discovery and development of the χ-conopeptide class of analgesic peptides. ( Lewis, RJ, 2012) |
| "Brivanib is a dual tyrosine kinase inhibitor with selectivity against VEFGR-2 and FGFR." | 2.47 | Brivanib alaninate for cancer. ( Diaz-Padilla, I; Siu, LL, 2011) |
| "Personalized cancer medicine aims to develop individualized treatment options adapted to factors relevant for the prognosis of each patient." | 2.46 | Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. ( Efferth, T, 2010) |
| "Brivanib (BMS-582664) is a novel, orally available and selective receptor tyrosine kinase inhibitor that targets the key angiogenesis receptors VEGF-R2 and FGF-R1 and -2." | 2.46 | Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor. ( Dempke, WC; Zippel, R, 2010) |
| "Our meta-analysis on total of 7,366 cancer cases and 9,102 controls from 13 published case-control studies showed no overall association of this polymorphism either with breast cancer risk or for cancer risk as such (for Ala homozygous odds ratio, 0." | 2.44 | Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. ( Bag, A; Bag, N, 2008) |
| "The chemoresistant tumors overexpress Bcl2/Bcl-xL/Mcl-1." | 2.43 | Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy. ( Basu, A; DuBois, G; Haldar, S, 2006) |
| "HBsAg-positive cancer patients treated with ETV (n = 582), TDF (n = 200) and TAF (n = 188) during chemotherapy were retrospectively enrolled." | 1.72 | Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. ( Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW, 2022) |
| "The overexpression of PRMT4 in several cancers has stimulated interest in the discovery of inhibitors as biological tools and, potentially, therapeutics." | 1.62 | Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*. ( Arrowsmith, CH; Barsyte, D; Bouché, L; Britton, R; Hartung, IV; Kaghad, A; Li, A; Li, F; Panagopoulos, D; Santhakumar, V; Scholten, C; Smil, D; Stellfeld, T; Steuber, H; Sutherland, M; Szewczyk, M; Vedadi, M, 2021) |
| "Most pediatric cancer patients with COVID-19 should have good clinical outcomes except for patients with critical infections." | 1.62 | Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country. ( Abdo, I; Abouelnaga, S; Al-Halfawy, A; El-Ansary, MG; Elhaddad, A; Elmeniawy, S; Hammad, M; Hassan, R; Khamis, N; Madeny, Y; Mansour, T; Shalaby, L; Sherief, N; Sidhom, I; Soliman, S; Zaki, I, 2021) |
| "Among 2,186 U." | 1.56 | Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. ( Arcobello, J; Bakouny, Z; Choueiri, TK; de Lima Lopes, G; Doroshow, DB; Egan, PC; Farmakiotis, D; Fecher, LA; Friese, CR; Galsky, MD; Goel, S; Grivas, P; Gupta, S; Halfdanarson, TR; Halmos, B; Hawley, JE; Hsu, CY; Khaki, AR; Kuderer, NM; Lee, BJ; Lemmon, CA; Lyman, GH; Mishra, S; Olszewski, AJ; Painter, CA; Panagiotou, OA; Pennell, NA; Peters, S; Puc, MM; Revankar, SG; Rini, BI; Rivera, DR; Rubinstein, SM; Schapira, L; Schmidt, A; Schwartz, GK; Shah, DP; Shah, SA; Shyr, Y; Thompson, MA; Warner, JL; Wu, JT; Xie, Z; Yeh, AC; Zhu, H, 2020) |
| "Plasma samples from 56 gastric cancer patients, 28 breast cancer patients, 33 thyroid cancer patients, and 137 age-matched healthy controls were collected in the study." | 1.42 | Perioperative dynamics and significance of amino acid profiles in patients with cancer. ( Chen, T; Ding, S; Fu, S; Gu, Y; Lu, Y; Ruan, G; Sun, X; Teng, L; Wang, J; Wang, L; Wang, M, 2015) |
| "A significant proportion of cancer patients is treated using MeV electron radiation." | 1.38 | Relative response of alanine dosemeters for high-energy electrons determined using a Fricke primary standard. ( Anton, M; Boillat, B; Vörös, S, 2012) |
| "Mucositis is one of the most frequent side effects induced by chemotherapy that damages the patients' QOL and response rate." | 1.37 | [The effects of Rebamipide and Polaprezinc mouthwash and uptake on mucositis induced by chemotherapy]. ( Fukuhara, K; Hayaishi, Y; Katsuragi, K; Kodama, S; Morisya, Y; Nakanishi, C; Terakura, M, 2011) |
| "The results between cancer-activated and tissue factor-activated blood were similar." | 1.34 | Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. ( Cloonan, ME; DiNapoli, M; Mousa, SA, 2007) |
| "Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by mutations in the mismatch-repair genes." | 1.31 | The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. ( Bonner, JD; Boyd, J; Chong, G; De La Chapelle, A; Ellis, NA; Farber, D; Figer, A; Foulkes, WD; Friedman, E; Gaff, CL; Gebert, J; Gordon, PH; Greenwood, CM; Gregersen, PK; Gruber, SB; Hamel, N; Hampel, H; Horwitz, M; King, MC; Lee, C; MacNamara, E; Macrae, FA; Marcus, V; Markowitz, A; Nafa, K; Offit, K; Paillerets, BB; Rennert, G; Shia, J; Thiffault, I; Tomsho, L; Walsh, T; Weitzel, JN, 2002) |
| "In addition, cancer patients had a lower average cumulative amino acid exchange rate than non-tumor-bearing subjects, suggesting that the abnormally low relative glutamate exchange capacity of cancer patients results mainly from inadequate postabsorptive protein catabolism in the skeletal muscle tissue." | 1.30 | Linkage between postabsorptive amino acid release and glutamate uptake in skeletal muscle tissue of healthy young subjects, cancer patients, and the elderly. ( Babylon, A; Breitkreutz, R; Dröge, W; Hack, V; Holm, E; Tokus, M, 1997) |
| "L-alanosine (NSC 15353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism." | 1.27 | Phase I study of L-alanosine (NSC 15353). ( Goldsmith, MA; Greenspan, EM; Holland, JF; Ohnuma, T; Spigelman, M, 1983) |
| "In lung cancer tissue, the activity of aminopeptidase toward L-leucinamide was abnormally low, while the activity of arylamidase toward L-leucyl-beta-napthylamide was similar to that in normal lung." | 1.25 | Aminopeptidases and arylamidases in normal and cancer tissues in humans. ( Arima, T; Fujii, S; Niinobe, M; Okuda, H; Tamura, Y, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (23.40) | 18.7374 |
| 1990's | 6 (6.38) | 18.2507 |
| 2000's | 20 (21.28) | 29.6817 |
| 2010's | 29 (30.85) | 24.3611 |
| 2020's | 17 (18.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cordes, T | 2 |
| Kuna, RS | 1 |
| McGregor, GH | 1 |
| Khare, SV | 1 |
| Gengatharan, J | 2 |
| Muthusamy, T | 2 |
| Metallo, CM | 2 |
| Xiu, M | 1 |
| Li, L | 2 |
| Li, Y | 1 |
| Gao, Y | 1 |
| Lee, IC | 1 |
| Lan, KH | 1 |
| Su, CW | 1 |
| Li, CP | 1 |
| Chao, Y | 1 |
| Lin, HC | 1 |
| Hou, MC | 1 |
| Huang, YH | 1 |
| van den Elzen, P | 1 |
| Sander, T | 1 |
| Palmans, H | 1 |
| McManus, M | 1 |
| Woodall, N | 1 |
| Lee, N | 1 |
| Fox, OJL | 1 |
| Jones, RM | 1 |
| Angal-Kalinin, D | 1 |
| Subiel, A | 1 |
| Liu, H | 1 |
| Su, H | 1 |
| Wang, F | 2 |
| Dang, Y | 1 |
| Ren, Y | 1 |
| Yin, S | 1 |
| Lu, H | 1 |
| Zhang, H | 1 |
| Wu, J | 1 |
| Xu, Z | 1 |
| Zheng, M | 1 |
| Gao, J | 1 |
| Cao, Y | 1 |
| Xu, J | 1 |
| Chen, L | 1 |
| Wu, X | 1 |
| Ma, M | 1 |
| Xu, L | 2 |
| Chen, J | 1 |
| Su, C | 1 |
| Wu, C | 1 |
| Xie, H | 1 |
| Gu, J | 1 |
| Xi, JJ | 1 |
| Ge, B | 1 |
| Fei, Y | 1 |
| Chen, C | 1 |
| Jones, RL | 1 |
| Ratain, MJ | 1 |
| O'Dwyer, PJ | 1 |
| Siu, LL | 2 |
| Jassem, J | 1 |
| Medioni, J | 1 |
| DeJonge, M | 1 |
| Rudin, C | 1 |
| Sawyer, M | 1 |
| Khayat, D | 1 |
| Awada, A | 1 |
| de Vos-Geelen, JMPGM | 1 |
| Evans, TRJ | 1 |
| Obel, J | 1 |
| Brockstein, B | 1 |
| DeGreve, J | 1 |
| Baurain, JF | 1 |
| Maki, R | 1 |
| D'Adamo, D | 1 |
| Dickson, M | 1 |
| Undevia, S | 1 |
| Geary, D | 1 |
| Janisch, L | 1 |
| Bedard, PL | 1 |
| Abdul Razak, AR | 1 |
| Kristeleit, R | 1 |
| Vitfell-Rasmussen, J | 1 |
| Walters, I | 1 |
| Kaye, SB | 1 |
| Schwartz, G | 1 |
| Yadav, N | 1 |
| Gogada, R | 1 |
| O'Malley, J | 1 |
| Gundampati, RK | 1 |
| Jayanthi, S | 1 |
| Hashmi, S | 1 |
| Lella, R | 1 |
| Zhang, D | 1 |
| Wang, J | 2 |
| Kumar, R | 2 |
| Suresh Kumar, TK | 1 |
| Chandra, D | 1 |
| Lee, CJ | 1 |
| Qiu, TA | 1 |
| Sweedler, JV | 1 |
| Rivera, DR | 1 |
| Peters, S | 1 |
| Panagiotou, OA | 1 |
| Shah, DP | 1 |
| Kuderer, NM | 1 |
| Hsu, CY | 1 |
| Rubinstein, SM | 1 |
| Lee, BJ | 1 |
| Choueiri, TK | 1 |
| de Lima Lopes, G | 1 |
| Grivas, P | 1 |
| Painter, CA | 1 |
| Rini, BI | 1 |
| Thompson, MA | 1 |
| Arcobello, J | 1 |
| Bakouny, Z | 1 |
| Doroshow, DB | 1 |
| Egan, PC | 1 |
| Farmakiotis, D | 1 |
| Fecher, LA | 1 |
| Friese, CR | 1 |
| Galsky, MD | 1 |
| Goel, S | 1 |
| Gupta, S | 1 |
| Halfdanarson, TR | 1 |
| Halmos, B | 1 |
| Hawley, JE | 1 |
| Khaki, AR | 1 |
| Lemmon, CA | 1 |
| Mishra, S | 1 |
| Olszewski, AJ | 1 |
| Pennell, NA | 1 |
| Puc, MM | 1 |
| Revankar, SG | 1 |
| Schapira, L | 1 |
| Schmidt, A | 1 |
| Schwartz, GK | 1 |
| Shah, SA | 1 |
| Wu, JT | 1 |
| Xie, Z | 1 |
| Yeh, AC | 1 |
| Zhu, H | 2 |
| Shyr, Y | 1 |
| Lyman, GH | 1 |
| Warner, JL | 1 |
| Handzlik, MK | 1 |
| You, L | 1 |
| Lim, EW | 1 |
| Pinto, AFM | 1 |
| Badur, MG | 1 |
| Kolar, MJ | 1 |
| Wallace, M | 1 |
| Saghatelian, A | 1 |
| Simko, V | 1 |
| Belvoncikova, P | 1 |
| Csaderova, L | 1 |
| Labudova, M | 1 |
| Grossmannova, K | 1 |
| Zatovicova, M | 1 |
| Kajanova, I | 1 |
| Skultety, L | 1 |
| Barathova, M | 1 |
| Pastorek, J | 1 |
| Patra, B | 1 |
| Sharma, M | 1 |
| Hale, W | 1 |
| Utz, M | 1 |
| Walczak, M | 1 |
| Chryplewicz, A | 1 |
| Olewińska, S | 1 |
| Psurski, M | 1 |
| Winiarski, Ł | 1 |
| Torzyk, K | 1 |
| Oleksyszyn, J | 1 |
| Sieńczyk, M | 1 |
| Printz, C | 1 |
| Sutherland, M | 1 |
| Li, A | 1 |
| Kaghad, A | 1 |
| Panagopoulos, D | 1 |
| Li, F | 1 |
| Szewczyk, M | 1 |
| Smil, D | 1 |
| Scholten, C | 1 |
| Bouché, L | 1 |
| Stellfeld, T | 1 |
| Arrowsmith, CH | 1 |
| Barsyte, D | 1 |
| Vedadi, M | 1 |
| Hartung, IV | 1 |
| Steuber, H | 1 |
| Britton, R | 1 |
| Santhakumar, V | 1 |
| Rogado, J | 1 |
| Gullón, P | 1 |
| Obispo, B | 1 |
| Serrano, G | 1 |
| Lara, MÁ | 1 |
| White, E | 1 |
| Lattime, EC | 1 |
| Guo, JY | 1 |
| Hammad, M | 1 |
| Shalaby, L | 1 |
| Sidhom, I | 1 |
| Sherief, N | 1 |
| Abdo, I | 1 |
| Soliman, S | 1 |
| Madeny, Y | 1 |
| Hassan, R | 1 |
| Elmeniawy, S | 1 |
| Khamis, N | 1 |
| Zaki, I | 1 |
| Mansour, T | 1 |
| El-Ansary, MG | 1 |
| Al-Halfawy, A | 1 |
| Abouelnaga, S | 1 |
| Elhaddad, A | 1 |
| Kageyama, S | 1 |
| Ii, H | 1 |
| Taniguchi, K | 1 |
| Kubota, S | 1 |
| Yoshida, T | 1 |
| Isono, T | 1 |
| Chano, T | 1 |
| Yoshiya, T | 1 |
| Ito, K | 1 |
| Yoshiki, T | 1 |
| Kawauchi, A | 1 |
| Nakata, S | 1 |
| Yamashita, T | 1 |
| Mizohata, E | 1 |
| Nagatoishi, S | 1 |
| Watanabe, T | 1 |
| Nakakido, M | 1 |
| Iwanari, H | 1 |
| Mochizuki, Y | 1 |
| Nakayama, T | 1 |
| Kado, Y | 1 |
| Yokota, Y | 1 |
| Matsumura, H | 1 |
| Kawamura, T | 1 |
| Kodama, T | 1 |
| Hamakubo, T | 1 |
| Inoue, T | 1 |
| Fujitani, H | 1 |
| Tsumoto, K | 1 |
| Ghasemitarei, M | 1 |
| Yusupov, M | 1 |
| Razzokov, J | 1 |
| Shokri, B | 1 |
| Bogaerts, A | 1 |
| Floyd, RA | 1 |
| Castro Faria Neto, HC | 1 |
| Zimmerman, GA | 1 |
| Hensley, K | 1 |
| Towner, RA | 1 |
| Malm, M | 1 |
| Kronqvist, N | 1 |
| Lindberg, H | 1 |
| Gudmundsdotter, L | 1 |
| Bass, T | 1 |
| Frejd, FY | 1 |
| Höidén-Guthenberg, I | 1 |
| Varasteh, Z | 1 |
| Orlova, A | 1 |
| Tolmachev, V | 1 |
| Ståhl, S | 1 |
| Löfblom, J | 1 |
| Guidelli, EJ | 1 |
| Baffa, O | 1 |
| Qin, Q | 1 |
| Lu, J | 1 |
| Cheng, H | 1 |
| Zhan, L | 1 |
| Yang, X | 1 |
| Zhang, C | 1 |
| Sun, X | 2 |
| Adeva-Andany, M | 1 |
| López-Ojén, M | 1 |
| Funcasta-Calderón, R | 1 |
| Ameneiros-Rodríguez, E | 1 |
| Donapetry-García, C | 1 |
| Vila-Altesor, M | 1 |
| Rodríguez-Seijas, J | 1 |
| Townsend, DM | 1 |
| Lushchak, VI | 1 |
| Cooper, AJ | 2 |
| Gu, Y | 1 |
| Chen, T | 1 |
| Fu, S | 1 |
| Wang, L | 1 |
| Lu, Y | 1 |
| Ding, S | 1 |
| Ruan, G | 1 |
| Teng, L | 1 |
| Wang, M | 1 |
| Pant, S | 1 |
| Jones, SF | 1 |
| Kurkjian, CD | 1 |
| Infante, JR | 1 |
| Moore, KN | 1 |
| Burris, HA | 2 |
| McMeekin, DS | 1 |
| Benhadji, KA | 1 |
| Patel, BKR | 1 |
| Frenzel, MJ | 1 |
| Kursar, JD | 1 |
| Zamek-Gliszczynski, MJ | 1 |
| Yuen, ESM | 1 |
| Chan, EM | 1 |
| Bendell, JC | 1 |
| Xiao, YX | 1 |
| Yang, WX | 1 |
| Sattarinezhad, E | 1 |
| Bordbar, AK | 1 |
| Fani, N | 1 |
| Kindler, HL | 1 |
| Sandler, AB | 1 |
| Oliff, IA | 1 |
| Bag, A | 1 |
| Bag, N | 1 |
| Laroche-Pierre, S | 1 |
| Jodoin, J | 1 |
| LeBlanc, AC | 1 |
| Ierano, C | 1 |
| Giuliano, P | 1 |
| D'Alterio, C | 1 |
| Cioffi, M | 1 |
| Mettivier, V | 1 |
| Portella, L | 1 |
| Napolitano, M | 1 |
| Barbieri, A | 1 |
| Arra, C | 1 |
| Liguori, G | 1 |
| Franco, R | 1 |
| Palmieri, G | 1 |
| Rozzo, C | 1 |
| Pacelli, R | 1 |
| Castello, G | 1 |
| Scala, S | 1 |
| Huang, X | 1 |
| Huo, K | 1 |
| Cheng, X | 1 |
| Cao, P | 1 |
| Ji, X | 1 |
| Lu, W | 1 |
| Cai, X | 1 |
| Hu, C | 1 |
| Wang, Z | 1 |
| Zhang, S | 1 |
| Efferth, T | 1 |
| Mekhail, T | 1 |
| Masson, E | 3 |
| Fischer, BS | 1 |
| Gong, J | 2 |
| Iyer, R | 1 |
| Gan, J | 2 |
| Pursley, J | 2 |
| Patricia, D | 1 |
| Williams, D | 2 |
| Ganapathi, R | 1 |
| Meng, M | 1 |
| Chen, S | 1 |
| Lao, T | 1 |
| Liang, D | 1 |
| Sang, N | 1 |
| Dempke, WC | 1 |
| Zippel, R | 1 |
| Jonker, DJ | 1 |
| Rosen, LS | 1 |
| Sawyer, MB | 1 |
| de Braud, F | 1 |
| Wilding, G | 1 |
| Sweeney, CJ | 1 |
| Jayson, GC | 1 |
| McArthur, GA | 1 |
| Rustin, G | 1 |
| Goss, G | 1 |
| Kantor, J | 1 |
| Velasquez, L | 1 |
| Syed, S | 2 |
| Mokliatchouk, O | 1 |
| Feltquate, DM | 1 |
| Kollia, G | 2 |
| Nuyten, DSA | 1 |
| Galbraith, S | 1 |
| Caceres-Cortes, J | 1 |
| Christopher, LJ | 1 |
| Arora, V | 1 |
| Allentoff, A | 1 |
| Lago, M | 1 |
| Tran, SB | 1 |
| Iyer, RA | 1 |
| Diaz-Padilla, I | 1 |
| LoRusso, P | 1 |
| Shapiro, GI | 1 |
| Hurwitz, H | 1 |
| Pilat, MJ | 1 |
| Chemidlin, J | 1 |
| Fischer, B | 1 |
| Pinto, JT | 1 |
| Callery, PS | 1 |
| Lewis, RJ | 1 |
| Fukuhara, K | 1 |
| Terakura, M | 1 |
| Katsuragi, K | 1 |
| Kodama, S | 1 |
| Morisya, Y | 1 |
| Hayaishi, Y | 1 |
| Nakanishi, C | 1 |
| Vörös, S | 1 |
| Anton, M | 1 |
| Boillat, B | 1 |
| Chou, T | 1 |
| Finn, RS | 1 |
| Gerstner, RB | 1 |
| Carter, P | 1 |
| Lowman, HB | 1 |
| Foulkes, WD | 1 |
| Thiffault, I | 1 |
| Gruber, SB | 1 |
| Horwitz, M | 1 |
| Hamel, N | 1 |
| Lee, C | 1 |
| Shia, J | 1 |
| Markowitz, A | 1 |
| Figer, A | 1 |
| Friedman, E | 1 |
| Farber, D | 1 |
| Greenwood, CM | 1 |
| Bonner, JD | 1 |
| Nafa, K | 1 |
| Walsh, T | 1 |
| Marcus, V | 1 |
| Tomsho, L | 1 |
| Gebert, J | 1 |
| Macrae, FA | 1 |
| Gaff, CL | 1 |
| Paillerets, BB | 1 |
| Gregersen, PK | 1 |
| Weitzel, JN | 1 |
| Gordon, PH | 1 |
| MacNamara, E | 1 |
| King, MC | 1 |
| Hampel, H | 1 |
| De La Chapelle, A | 1 |
| Boyd, J | 1 |
| Offit, K | 1 |
| Rennert, G | 1 |
| Chong, G | 1 |
| Ellis, NA | 1 |
| McFadden, JM | 1 |
| Frehywot, GL | 1 |
| Townsend, CA | 1 |
| Altieri, DC | 1 |
| Ciesielski, B | 1 |
| Schultka, K | 1 |
| Kobierska, A | 1 |
| Nowak, R | 1 |
| Peimel-Stuglik, Z | 1 |
| Fernández, A | 1 |
| JACQUEZ, JA | 1 |
| STOCK, CC | 1 |
| BARCLAY, RK | 1 |
| PETROVA, MF | 1 |
| PUKHAL'SKAIA, ECh | 1 |
| MEN'SHIKOV, GP | 1 |
| BUSCH, H | 1 |
| DAVIS, JR | 1 |
| ANDERSON, DC | 1 |
| KOJIMA, M | 1 |
| MELONI, GA | 1 |
| GENTY, N | 1 |
| VENDRELY, R | 1 |
| ATCHLEY, WA | 1 |
| BHAGAVAN, NV | 1 |
| KIT, S | 2 |
| GREENBERG, DM | 2 |
| Vadlamudi, RK | 1 |
| Bagheri-Yarmand, R | 1 |
| Yang, Z | 1 |
| Balasenthil, S | 1 |
| Nguyen, D | 1 |
| Sahin, AA | 1 |
| den Hollander, P | 1 |
| Mikawa, M | 1 |
| Wang, H | 2 |
| Guo, L | 1 |
| Liu, R | 1 |
| Marik, J | 1 |
| Takada, Y | 1 |
| Lam, K | 1 |
| Lau, D | 1 |
| Cheng, JD | 1 |
| Valianou, M | 1 |
| Canutescu, AA | 1 |
| Jaffe, EK | 1 |
| Lee, HO | 1 |
| Lai, JH | 1 |
| Bachovchin, WW | 1 |
| Weiner, LM | 1 |
| Capella, G | 1 |
| Caldas, C | 1 |
| Basu, A | 1 |
| DuBois, G | 1 |
| Haldar, S | 1 |
| Debniak, T | 1 |
| Scott, RJ | 1 |
| Huzarski, T | 1 |
| Byrski, T | 1 |
| Rozmiarek, A | 1 |
| Debniak, B | 1 |
| Górski, B | 1 |
| Cybulski, C | 1 |
| Medrek, K | 1 |
| Mierzejewski, M | 1 |
| Masojc, B | 1 |
| Matyjasik, J | 1 |
| Złowocka, E | 1 |
| Teodorczyk, U | 1 |
| Lener, M | 1 |
| Klujszo-Grabowska, E | 1 |
| Nej-Wołosiak, K | 1 |
| Jaworowska, E | 1 |
| Oszutowska, D | 1 |
| Szymańska, A | 1 |
| Szymańska, J | 1 |
| Castaneda, J | 1 |
| van de Wetering, T | 1 |
| Suchy, J | 1 |
| Kurzawski, G | 1 |
| Oszurek, O | 1 |
| Narod, S | 1 |
| Lubinski, J | 1 |
| Chaurasia, P | 1 |
| Aguirre-Ghiso, JA | 1 |
| Liang, OD | 1 |
| Gardsvoll, H | 1 |
| Ploug, M | 1 |
| Ossowski, L | 1 |
| Zupnick, A | 1 |
| Prives, C | 1 |
| Vitale, L | 1 |
| Frabetti, F | 1 |
| Huntsman, SA | 1 |
| Canaider, S | 1 |
| Casadei, R | 1 |
| Lenzi, L | 1 |
| Facchin, F | 1 |
| Carinci, P | 1 |
| Zannotti, M | 1 |
| Coppola, D | 1 |
| Strippoli, P | 1 |
| Cloonan, ME | 1 |
| DiNapoli, M | 1 |
| Mousa, SA | 1 |
| Goldsmith, MA | 1 |
| Ohnuma, T | 1 |
| Spigelman, M | 1 |
| Greenspan, EM | 1 |
| Holland, JF | 1 |
| Powis, G | 1 |
| Kovach, JS | 1 |
| Tatara, T | 1 |
| Noguchi, J | 1 |
| Fukushima, K | 1 |
| Ishihara, Y | 1 |
| Ohkochi, S | 1 |
| Uedaira, H | 1 |
| Nichiporov, D | 1 |
| Kostjuchenko, V | 1 |
| Puhl, JM | 1 |
| Bensen, DL | 1 |
| Desrosiers, MF | 1 |
| Dick, CE | 1 |
| McLaughlin, WL | 1 |
| Kojima, T | 1 |
| Coursey, BM | 1 |
| Zink, S | 1 |
| Holm, E | 1 |
| Hack, V | 1 |
| Tokus, M | 1 |
| Breitkreutz, R | 1 |
| Babylon, A | 1 |
| Dröge, W | 1 |
| Lavelle, F | 1 |
| Waterhouse, C | 1 |
| Jeanpretre, N | 1 |
| Keilson, J | 1 |
| Searle, GL | 1 |
| Tamura, Y | 1 |
| Niinobe, M | 1 |
| Arima, T | 1 |
| Okuda, H | 1 |
| Fujii, S | 1 |
| Kriat, M | 1 |
| Vion-Dury, J | 1 |
| Fayre, R | 1 |
| Maraninchi, D | 1 |
| Harlé, JR | 1 |
| Confort-Gouny, S | 1 |
| Sciaky, M | 1 |
| Fontanarava, E | 1 |
| Viout, P | 1 |
| Cozzone, PJ | 1 |
| Heimbrook, DC | 1 |
| Stirdivant, SM | 1 |
| Ahern, JD | 1 |
| Balishin, NL | 1 |
| Patrick, DR | 1 |
| Edwards, GM | 1 |
| Defeo-Jones, D | 1 |
| FitzGerald, DJ | 1 |
| Pastan, I | 1 |
| Oliff, A | 1 |
| Mallinger, AG | 1 |
| Jozwiak, EL | 1 |
| Carter, JC | 1 |
| DeWys, WD | 1 |
| Hall, TC | 1 |
| Teichmann, B | 1 |
| Ziebarth, D | 1 |
| Hahn, K | 1 |
| Ladner, HA | 1 |
| Jesdinsky, HJ | 1 |
| Unger, RH | 1 |
| Kellen, JA | 1 |
| Lustig, V | 1 |
| Ohno, R | 1 |
| Hersh, EM | 1 |
| Björnesjö, KB | 2 |
| Jarnulf, B | 1 |
| Lausing, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study of a Notch Inhibitor in Patients With Advanced Cancer[NCT01158404] | Phase 1 | 35 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy[NCT00207051] | Phase 1 | 62 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| The RETORNUS Study: Dual Training to Restore the Function of Respiratory Muscles in Stroke Patients[NCT02125760] | 129 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Best overall response of stable disease or better is complete response (CR) + partial response (PR) + stable disease (SD) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines (version 1.1). CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Percentage of Participants with a best overall response of SD or better is calculated as a total number of participants with CR or PR or SD divided by the total number of participants treated then multiplied by 100. (NCT01158404)
Timeframe: Baseline to measured progressive disease up to 15.1 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 2 mg LY900009 - Dose Escalation Phase (Part A) | 33.3 |
| 4 mg LY900009 - Dose Escalation Phase (Part A) | 0 |
| 8 mg LY900009 - Dose Escalation Phase (Part A) | 66.7 |
| 15 mg LY900009 - Dose Escalation Phase (Part A) | 33.3 |
| 30 mg LY900009 - Dose Escalation Phase (Part A) | 16.7 |
| 45 mg LY900009 - Dose Escalation Phase (Part A) | 0 |
| 60 mg LY900009 - Dose Escalation Phase (Part A) | 0 |
| 30 mg LY900009 - Dose Confirmation Phase (Part B) | 0 |
The geometric mean AUC(0-infinity) for each dose group is reported following a single dose of LY900009. (NCT01158404)
Timeframe: Day1: Pre-dose, 0.5 hours (hr), 1 hr, 3-4 hr, 6-8 hr and 24-30 hours post-dose
| Intervention | nanograms*hour/milliliters (ng*h/mL) (Geometric Mean) |
|---|---|
| 2 mg LY900009 - Dose Escalation Phase (Part A) | NA |
| 4 mg LY900009 - Dose Escalation Phase (Part A) | 31.6 |
| 8 mg LY900009 - Dose Escalation Phase (Part A) | 76.2 |
| 15 mg LY900009 - Dose Escalation Phase (Part A) | 121 |
| 30 mg LY900009 - Dose Escalation/Confirmation Phase (Part A,B) | 315 |
| 45 mg LY900009 - Dose Escalation Phase (Part A) | 547 |
| 60 mg LY900009 - Dose Escalation Phase (Part A) | 1240 |
The geometric mean Cmax for each dose group is reported following a single dose of LY900009. (NCT01158404)
Timeframe: Day1: Pre-dose, 0.5 hours (hr), 1 hr, 3-4 hr, 6-8 hr and 24-30 hours post-dose
| Intervention | nanograms/milliliter (ng/mL) (Geometric Mean) |
|---|---|
| 2 mg LY900009 - Dose Escalation Phase (Part A) | 4.03 |
| 4 mg LY900009 - Dose Escalation Phase (Part A) | 11.7 |
| 8 mg LY900009 - Dose Escalation Phase (Part A) | 20.2 |
| 15 mg LY900009 - Dose Escalation Phase (Part A) | 27.4 |
| 30 mg LY900009 - Dose Escalation/Confirmation Phase (Part A,B) | 71.2 |
| 45 mg LY900009 - Dose Escalation Phase (Part A) | 96.2 |
| 60 mg LY900009 - Dose Escalation Phase (Part A) | 158 |
Recommended Phase 2 dose was determined by the maximum tolerated dose (MTD). MTD is the highest dose with <33% of participants having a dose-limiting toxicity (DLT) during Cycle 1. DLT is an adverse event (AE) occurring for a participant enrolled in Part A that is likely related to the study drug and fulfills any 1 of the following: Common Terminology Criteria for AE (CTCAE, Version 4.02) Grade 3 or 4 nonhematologic toxicity except for Grade 3 nausea, vomiting or electrolyte disturbance; Grade 3 nausea, vomiting or electrolyte disturbance that persists more than 2 days despite maximal supportive intervention; Grade 4 hematological toxicity that persists more than 5 days; Grade 3 or 4 thrombocytopenia with bleeding; Grade 3 or 4 neutropenia with fever. A DLT can be declared if a participant experiences increasing toxicity during treatment. (NCT01158404)
Timeframe: Predose up to 28 days in Cycle 1
| Intervention | milligrams (mg) (Number) |
|---|---|
| LY900009 - Dose Escalation Phase (Part A) | 30 |
Clinically significant effects are study drug related serious adverse events (SAEs) and study drug related treatment emergent adverse events (TEAEs). A summary of all SAEs and all other non-SAEs regardless of causality is located in the Reported Adverse Events module. (NCT01158404)
Timeframe: Baseline to study completion up to 18.7 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| SAEs | TEAEs | |
| 15 mg LY900009 - Dose Escalation Phase (Part A) | 0 | 3 |
| 2 mg LY900009 - Dose Escalation Phase (Part A) | 0 | 2 |
| 30 mg LY900009 - Dose Confirmation Phase (Part B) | 2 | 6 |
| 30 mg LY900009 - Dose Escalation Phase (Part A) | 0 | 5 |
| 4 mg LY900009 - Dose Escalation Phase (Part A) | 1 | 1 |
| 45 mg LY900009 - Dose Escalation Phase (Part A) | 0 | 5 |
| 60 mg LY900009 - Part A: Dose Escalation | 1 | 2 |
| 8 mg LY900009 - Dose Escalation Phase (Part A) | 0 | 3 |
18 reviews available for alanine and Benign Neoplasms
| Article | Year |
|---|---|
An update regarding the role of WNK kinases in cancer.
Topics: Alanine; Animals; Bicarbonates; Mammals; Neoplasms; Neovascularization, Pathologic; Proline; Serine; | 2022 |
d-Alanine: Distribution, origin, physiological relevance, and implications in disease.
Topics: Alanine; Animals; Diabetes Mellitus; Humans; Kidney Diseases; Liver Cirrhosis; Mental Disorders; Neo | 2020 |
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity.
Topics: Adaptive Immunity; Alanine; Animals; Antineoplastic Agents; Arginine; Autophagy; Drug Resistance, Ne | 2021 |
Mechanisms of Tumor Growth Inhibition by Depletion of γ-Glutamylcyclotransferase (GGCT): A Novel Molecular Target for Anticancer Therapy.
Topics: Alanine; Enzyme Inhibitors; gamma-Glutamylcyclotransferase; Gene Expression Regulation, Enzymologic; | 2018 |
Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.
Topics: Alanine; Antineoplastic Agents; Benzenesulfonates; Cyclic N-Oxides; Drug Combinations; Free Radicals | 2013 |
PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies.
Topics: Alanine; Case-Control Studies; Genetic Predisposition to Disease; Humans; Neoplasms; Poly (ADP-Ribos | 2014 |
Comprehensive review on lactate metabolism in human health.
Topics: Alanine; Carbon Dioxide; Diabetes Mellitus; Glucose; Humans; Lactic Acid; Metabolic Networks and Pat | 2014 |
KIFC1: a promising chemotherapy target for cancer treatment?
Topics: Alanine; Antineoplastic Agents; Centrosome; DNA; Female; Humans; Kinesins; Mitosis; Molecular Target | 2016 |
Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review.
Topics: Alanine; Alleles; Antioxidants; Breast Neoplasms; Genetic Predisposition to Disease; Humans; Neoplas | 2008 |
IGFBP3 polymorphisms and risk of cancer: a meta-analysis.
Topics: Alanine; Alleles; Amino Acid Substitution; Case-Control Studies; Confidence Intervals; Genetic Predi | 2010 |
Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products.
Topics: Alanine; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biolo | 2010 |
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Topics: Alanine; Clinical Trials as Topic; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, | 2010 |
Brivanib alaninate for cancer.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Scr | 2011 |
Reversible and irreversible protein glutathionylation: biological and clinical aspects.
Topics: Alanine; Aldehydes; Alzheimer Disease; Apoptosis; Busulfan; Cataract; Cell Cycle; Cystic Fibrosis; D | 2011 |
Discovery and development of the χ-conopeptide class of analgesic peptides.
Topics: Alanine; Amino Acid Sequence; Analgesics; Animals; Chronic Pain; Conotoxins; Humans; Molecular Seque | 2012 |
Brivanib: a review of development.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Screening Assays, Antitumo | 2012 |
Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy.
Topics: Alanine; Animals; Apoptosis; bcl-X Protein; Cell Death; Cytoplasm; DNA, Complementary; Humans; Mice; | 2006 |
The use of isotope turnover techniques in the study of carbohydrate metabolism in man.
Topics: Acromegaly; Alanine; Blood Glucose; Carbohydrate Metabolism; Carbon Dioxide; Carbon Isotopes; Ethano | 1976 |
6 trials available for alanine and Benign Neoplasms
| Article | Year |
|---|---|
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Topics: Aged; Alanine; Antineoplastic Agents; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Male; Mi | 2019 |
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Alanine; Amyloid Precursor Protein Secretases; Antineoplastic Age | 2016 |
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Antimetabolites, Antineoplastic; Drug Administration Sche | 2009 |
Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Aged; Alanine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Do | 2010 |
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Respon | 2011 |
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Cross-Over Studies; Female; Food; Hu | 2011 |
70 other studies available for alanine and Benign Neoplasms
| Article | Year |
|---|---|
1-Deoxysphingolipid synthesis compromises anchorage-independent growth and plasma membrane endocytosis in cancer cells.
Topics: Agar; Alanine; Cell Membrane; Ceramides; Endocytosis; Metabolic Networks and Pathways; Neoplasms; Se | 2022 |
Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Topics: Acute Kidney Injury; Adenine; Alanine; Antiviral Agents; Cisplatin; Hepatitis B Surface Antigens; He | 2022 |
Alanine response to low energy synchrotron x-ray radiation.
Topics: Alanine; Brachytherapy; Graphite; Humans; Monte Carlo Method; Neoplasms; Radiometry; Synchrotrons; U | 2023 |
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity.
Topics: Alanine; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cisplatin; High-Throughput Screening Ass | 2023 |
Molecular insights on cytochrome c and nucleotide regulation of apoptosome function and its implication in cancer.
Topics: Alanine; Amino Acid Substitution; Apoptosomes; Apoptotic Protease-Activating Factor 1; Case-Control | 2020 |
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Betacoronavirus; Clinical Decision-Making; Coro | 2020 |
Serine restriction alters sphingolipid diversity to constrain tumour growth.
Topics: Alanine; Animals; Cell Adhesion; Cell Division; Diet; Female; Glycine; HCT116 Cells; Humans; Membran | 2020 |
PIMT Binding to C-Terminal Ala459 of CAIX Is Involved in Inside-Out Signaling Necessary for Its Catalytic Activity.
Topics: Alanine; Animals; Antigens, Neoplasm; Carbonic Anhydrase IX; Catalysis; Cell Hypoxia; Cell Movement; | 2020 |
Time-resolved non-invasive metabolomic monitoring of a single cancer spheroid by microfluidic NMR.
Topics: Alanine; Glucose; Glutamine; Humans; Hydrogen-Ion Concentration; Lab-On-A-Chip Devices; Lactic Acid; | 2021 |
Phosphonic Analogs of Alanine as Acylpeptide Hydrolase Inhibitors.
Topics: Alanine; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Esterification; Humans; Neopla | 2021 |
Research shows racial disparity, mortality data for patients with cancer and COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Black or African American; COVID-19; COVID-19 Dr | 2021 |
Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*.
Topics: Alanine; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; HE | 2021 |
Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
Topics: Adenosine Monophosphate; Aged; Alanine; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; C | 2021 |
Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country.
Topics: Adenosine Monophosphate; Adolescent; Alanine; Antiviral Agents; Child; Child, Preschool; COVID-19; D | 2021 |
Affinity Improvement of a Cancer-Targeted Antibody through Alanine-Induced Adjustment of Antigen-Antibody Interface.
Topics: Alanine; Amino Acid Substitution; Antibodies, Monoclonal; Antibody Affinity; Antigen-Antibody Comple | 2019 |
Transport of cystine across xC
Topics: Alanine; Amino Acid Substitution; Amino Acid Transport System y+; Antiporters; Arginine; Binding Sit | 2019 |
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Topics: Alanine; Animals; Biosensing Techniques; Cell Line, Tumor; Cell Proliferation; Cell Surface Display | 2013 |
Influence of photon beam energy on the dose enhancement factor caused by gold and silver nanoparticles: An experimental approach.
Topics: Alanine; Algorithms; Contrast Media; Electron Spin Resonance Spectroscopy; Gold; Humans; Metal Nanop | 2014 |
A comparison of reversible versus irreversible protein glutathionylation.
Topics: Alanine; Aminobutyrates; Enzymes; Gene Expression Regulation, Neoplastic; Glutaredoxins; Glutathione | 2014 |
Perioperative dynamics and significance of amino acid profiles in patients with cancer.
Topics: Alanine; Amino Acids; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Cell Pro | 2015 |
Virtual screening of Piperine analogs as Survivin inhibitors and their molecular interaction analysis by using consensus docking, MD simulation, MMPB/GBSA and alanine scanning techniques.
Topics: Alanine; Alkaloids; Benzodioxoles; Humans; Inhibitor of Apoptosis Proteins; Molecular Docking Simula | 2017 |
Helix 3 is necessary and sufficient for prion protein's anti-Bax function.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Animals; Apoptosis; bcl-2-Associated X Protei | 2009 |
A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Movement; Cel | 2009 |
Antitumour response of a double mutant of staphylococcal enterotoxin C2 with the decreased affinity for MHC class II molecule.
Topics: Alanine; Amino Acid Substitution; Animals; Antineoplastic Agents; Enterotoxins; Histocompatibility A | 2010 |
Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells.
Topics: Alanine; Ammonia; Aspartic Acid; Carbon; Cell Line, Tumor; Cell Proliferation; Energy Metabolism; Gl | 2010 |
Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Topics: Administration, Oral; Alanine; Animals; Antineoplastic Agents; Bile; Biotransformation; Feces; Human | 2011 |
[The effects of Rebamipide and Polaprezinc mouthwash and uptake on mucositis induced by chemotherapy].
Topics: Aged; Alanine; Antineoplastic Agents; Carnosine; Female; Humans; Male; Middle Aged; Mouthwashes; Muc | 2011 |
Relative response of alanine dosemeters for high-energy electrons determined using a Fricke primary standard.
Topics: Alanine; Calibration; Cobalt; Electrons; Equipment Design; Humans; Monte Carlo Method; Neoplasms; Pa | 2012 |
Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody.
Topics: Alanine; Amino Acid Substitution; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibod | 2002 |
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
Topics: Alanine; Case-Control Studies; Chromosomes, Human, Pair 2; Colorectal Neoplasms, Hereditary Nonpolyp | 2002 |
A flexible route to (5R)-thiolactomycin, a naturally occurring inhibitor of fatty acid synthesis.
Topics: Acetyltransferases; Alanine; Anti-Bacterial Agents; Fatty Acid Synthase, Type II; Fatty Acids; Human | 2002 |
Blocking survivin to kill cancer cells.
Topics: Alanine; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; DNA, Complementary; Genes, | 2003 |
In vivo alanine/EPR dosimetry in daily clinical practice: a feasibility study.
Topics: Alanine; Algorithms; Cobalt Radioisotopes; Electron Spin Resonance Spectroscopy; Feasibility Studies | 2003 |
Oncogenic mutations and packing defects in protein structure.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Arginine; Binding Sites; Glycine; Hydrogen Bo | 2003 |
Effect of beta-2-thienyl-DL-alanine on the growth of sarcoma T241 in C57 black mice.
Topics: Alanine; Animals; beta-Alanine; Black People; Humans; Mice; Neoplasms; Sarcoma; Sarcoma, Experimenta | 1953 |
[A preparation from Hippophae rhamnoides inhibiting growth of transplanted animal tumors].
Topics: Alanine; Animals; Antineoplastic Agents; Hippophae; Humans; Neoplasms; Plant Extracts | 1959 |
Labeling of nuclear proteins of tumors and other tissues in vitro with L-lysine-U-C14 and L-alanine-U-C14.
Topics: Alanine; Biochemical Phenomena; Humans; In Vitro Techniques; Lysine; Neoplasms; Nuclear Proteins; Nu | 1960 |
[TUMOR-FORMING LEUKEMIA (INCLUDING CHLOROMA)].
Topics: Adolescent; Alanine; Antineoplastic Agents; Child; Dexamethasone; Humans; Leukemia; Mechlorethamine; | 1963 |
[CONTRIBUTION TO THE STUDY OF RIBONUCLEOPROTEINS OF NORMAL AND NEOPLASTIC TISSUES].
Topics: Alanine; Arginine; Aspartic Acid; Chemical Phenomena; Chemistry; Glutamates; Glycine; Isoleucine; Le | 1963 |
SALINE-SOLUBLE PREPARATIONS OF DEOXYRIBONUCLEOPROTEINS.
Topics: Acetates; Alanine; Aminobutyrates; Aminocaproates; Aminocaproic Acid; Animals; Cadmium; Caprylates; | 1964 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. III. The rate of radioactive alanine and glycine uptake into the protein of lymphosarcoma cells and normal spleen cells.
Topics: Alanine; Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Radioactive Tracers; Sarcoma; Spleen | 1951 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. IV. The conversion of lactate-2-C14 to alanine, glutamate, and aspartate by tumor and spleen cells.
Topics: Alanine; Aspartic Acid; Glutamates; Glutamic Acid; Lactic Acid; Lymphoma; Lymphoma, Non-Hodgkin; Neo | 1951 |
Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.
Topics: Alanine; Apoptosis; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Cycle; Cell Division | 2004 |
Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells.
Topics: Alanine; Animals; Binding Sites; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Proliferation; CHO | 2004 |
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.
Topics: Alanine; Animals; Antigens, Neoplasm; Antineoplastic Agents; Binding Sites; Biomarkers, Tumor; Blott | 2005 |
MTAP homozygous deletion: an Achilles heel of human cancers ready for clinical use?
Topics: Adenosine Monophosphate; Alanine; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Resist | 2005 |
CDKN2A common variant and multi-organ cancer risk--a population-based study.
Topics: Adult; Aged; Alanine; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Female; Genes, p1 | 2006 |
A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.
Topics: Alanine; Biotinylation; Cell Line, Tumor; Crystallography, X-Ray; Humans; Integrin alpha5beta1; Mode | 2006 |
Mutational analysis of the p53 core domain L1 loop.
Topics: Alanine; Amino Acid Substitution; Arginine; Base Sequence; Binding Sites; DNA; DNA Mutational Analys | 2006 |
Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors.
Topics: Adult; Aged; Alanine; Alternative Splicing; Amino Acid Sequence; Animals; Base Sequence; Codon; Dige | 2007 |
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
Topics: Alanine; Cell Line, Tumor; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weight; Hum | 2007 |
Phase I study of L-alanosine (NSC 15353).
Topics: Adult; Aged; Alanine; Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Fe | 1983 |
Binding of copper and zinc by the antitumour agent L-alanosine.
Topics: Alanine; Animals; Chelating Agents; Copper; Humans; Lethal Dose 50; Leukemia P388; Male; Mice; Neopl | 1981 |
Proton NMR spectroscopic studies of serum as an aid to perioperative cellular metabolic monitoring.
Topics: Adult; Aged; Alanine; Blood Chemical Analysis; Blood Glucose; Esophageal Neoplasms; Fatty Acids, Non | 1995 |
Investigation of applicability of alanine and radiochromic detectors to dosimetry of proton clinical beams.
Topics: Alanine; Chromium Radioisotopes; Electron Spin Resonance Spectroscopy; Humans; Japan; Neoplasms; Par | 1995 |
Linkage between postabsorptive amino acid release and glutamate uptake in skeletal muscle tissue of healthy young subjects, cancer patients, and the elderly.
Topics: Adult; Aged; Alanine; Amino Acids; Glutamic Acid; Humans; Intestinal Absorption; Linear Models; Male | 1997 |
[Telomerases: transformation trial!].
Topics: Alanine; Antineoplastic Agents; Aspartic Acid; Catalytic Domain; Cell Division; DNA-Binding Proteins | 1999 |
Gluconeogenesis from alanine in patients with progressive malignant disease.
Topics: Adult; Aged; Alanine; Blood Glucose; Energy Metabolism; Fasting; Female; Gluconeogenesis; Glucose; H | 1979 |
Aminopeptidases and arylamidases in normal and cancer tissues in humans.
Topics: Alanine; Amides; Aminopeptidases; Colon; Digestive System; Humans; Ileum; Kidney; Leucine; Liver; Li | 1975 |
Variations of plasma sialic acid and N-acetylglucosamine levels in cancer, inflammatory diseases and bone marrow transplantation: a proton NMR spectroscopy study.
Topics: Acetylglucosamine; Alanine; Bone Marrow Transplantation; Humans; Inflammation; Longitudinal Studies; | 1991 |
Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.
Topics: ADP Ribose Transferases; Alanine; Animals; Antineoplastic Agents; Bacterial Toxins; Cell Line; Cloni | 1990 |
Preparation of boron-containing bovine -globulin as a model compound for a new approach to slow neutron therapy of tumors.
Topics: Alanine; Anhydrides; Animals; Boron Compounds; Boronic Acids; Cattle; Chromatography, Gel; Dipeptide | 1972 |
Anti-tumor effect of the amino acid minosine.
Topics: Alanine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Dose-Response Relationship, Drug; Ge | 1973 |
[The influence of lactic acid on crystallization patterns in cancer diagnosis. I. Cryoscopic measurements and studies on crystallization].
Topics: Alanine; Albumins; Animals; Chemical Phenomena; Chemistry, Physical; Chlorides; Copper; Crystallizat | 1973 |
[Concentration changes of free amino acids in blood plasma of patients under radiotherapy. (With reference to statistical results)].
Topics: Alanine; Amino Acids; Bronchial Neoplasms; Carcinoma; Cobalt Isotopes; Dysgerminoma; Esophageal Neop | 1972 |
Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses.
Topics: Adipose Tissue; Alanine; Bacterial Infections; Body Weight; Burns; Diabetes Mellitus; Dietary Carboh | 1971 |
Patterns of amino-acid inhibition of alkaline phosphatases as an aid in cancer diagnosis.
Topics: Adenocarcinoma; Alanine; Alkaline Phosphatase; Amino Acids; Animals; Arginine; Colonic Neoplasms; Fe | 1971 |
Immunosuppressive effects of L-asparaginase.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Alanine; Antibody Formation; Antigens; Asparaginase; Asparagin | 1970 |
The erythrocyte plasma distribution of amino acids in health and disease.
Topics: Acute Disease; Adolescent; Adult; Alanine; Amino Acids; Anemia, Hemolytic; Anemia, Pernicious; Bronc | 1968 |
Uptake of labelled amino acids into human erythrocytes in disease.
Topics: Acute Disease; Alanine; Amino Acids; Anemia; Bronchitis; Bronchopneumonia; Carbon Isotopes; Erythroc | 1968 |